Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 27, 2025
Discovery & Translation
Science Spotlight: Improving safety of live-attenuated vaccines
BioCentury’s roundup of translational innovations also includes base editing for prion disease, a Flagship collab, and six papers with links to newcos
BioCentury | Nov 4, 2024
Distillery Therapeutics
Inhibiting IFNγ or fibroblast-driven inflammation and vasodilation for rosacea
BioCentury | Nov 4, 2024
Distillery Therapeutics
T helper cells transiently expressing autoantigens for CNS injury
BioCentury | Oct 2, 2024
Distillery Therapeutics
Targeting Regnase-1 in NK cells for antitumor immunity
BioCentury | Feb 23, 2024
Product Development
Amgen sees rare diseases as ‘fourth pillar’ of growth, driven by pair of 2022 deals
The big biotech spotlights pipeline, outlines commercial steps critical for drugs from Horizon, ChemoCentryx takeouts to reach more patients
BioCentury | Jan 10, 2024
Deals
Aiolos team, VCs steer asthma start-up into quick $1B sale to GSK
Syndicate wins an exit 11 weeks after announcement of series A round to fund development of Phase II-ready asset from Hengrui
BioCentury | Oct 25, 2023
Emerging Company Profile
Aiolos: going for best in class with a long-acting TSLP mAb for asthma
Start-up, which launched with a $245M series A, is taking on AstraZeneca-Amgen drug with a mAb in-licensed from China-based Hengrui
BioCentury | Mar 8, 2023
Distillery Therapeutics
Inhibiting TBK1 to overcome resistance to immunotherapy
BioCentury | Jan 28, 2023
Discovery & Translation
CRISPR knockdown tech from Doudna lab; plus CAR Ts for myasthenia gravis and more
BioCentury’s roundup of translational news
BioCentury | May 26, 2022
Emerging Company Profile
Kinaset: targeting JAK to treat both asthma phenotypes
With a $40M series A and former head of Pulmatrix Robert Clarke as CEO, Kinaset is going upstream in the inflammatory pathway to treat both major types of asthma
Items per page:
1 - 10 of 342